To Assess Surfactant Levels in Lung Fluid
Conditions
Brief summary
NAME of STUDY: Surfactant levels in the lungs of COVID-19 patients BACKGROUND * Infection with SARS-CoV-2 may induce respiratory failure. * COVID-19 associated respiratory failure may require ventilatory support. * SARS-CoV-2 uses alveolar type II cells for virus replication. * Alveolar type II cells are responsible for surfactant production and lack of surfactant causes respiratory failure in preterm neonates. * Lack of surfactant may play role for respiratory failure in COVID-19 patients DESIGN Exploratory prospective study design without therapeutic intervention of any kind. Lung fluid will be donated as part of standard care procedures. HYPOTHESIS Surfactant is measurable in tracheal secretions by mid-infrared FTIR spectroscopy determined surfactant spectra. Surfactant is reduced in COVID-19 patients requiring ventilator support as compared to non- COVID-19 patients. Dysfunctional surfactant in COVID-19 patients regain its function when respiratory function improves. POPULATION Main population is patients with COVID-19 pneumonia that requires ventilatory support. OUTCOME MEASURES Primary outcome is the level of surfactant in lung fluid as obtained by tracheal suction. SAMPLE SIZE In total 30 patients will be included: twenty COVID-19 patients and 10 non-COVID-19 patients.
Interventions
DIAGNOSTIC_TESTSurfactant assessment
To determine surfactant levels in lung fluid
Sponsors
Zealand University Hospital
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients positive for coronavirus 2 (SARS-CoV-2) AND 2. Respiratory failure requiring mechanical ventilation support OR respiratory failure requiring oxygen supplementation AND 3. Age \> 18 years AND 4. Permission from next of kin
Exclusion criteria
Inability to obtain TS or BL as determined by clinical judgement by responsible clinician. Patients with known surfactant dysfunction (such as mutations in the SFTPB or ABCA3 gene). Imminent expected death within 24 hours. Stage 4 severe chronic kidney disease or requiring dialysis. Liver failure. Anticipated transfer to another hospital within 72 hours. Participation in another study which in the opinion of the investigator would prevent enrollment for safety purposes.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Surfactant | Two years | The primary outcome is surfactant levels in lung fluid |
Contacts
Primary ContactHenning B Nielsen
Outcome results
None listed